RNA-Based Therapeutics for Lipoprotein Metabolism Disorders

Abstract

Lipoprotein metabolism disorders, encompassing a spectrum of dyslipidemias such as familial hypercholesterolemia and hypertriglyceridemia, are intimately linked with increased cardiovascular risk. Recent advances in molecular medicine have catalyzed the development of RNA-based therapeutics targeting key components of lipid metabolism. This review synthesizes current scientific evidence regarding the mechanisms, clinical relevance, and therapeutic prospects of RNA-based interventions in lipoprotein metabolism disorders. We discuss epidemiological trends, pathophysiological mechanisms, risk stratification, clinical features, diagnostic approaches, and therapeutic paradigms, with an emphasis on emerging RNA-based agents. The article concludes with guideline recommendations and practical implications for clinicians managing these high-risk patients.

Introduction

Disorders of lipoprotein metabolism constitute a major public health challenge due to their role as modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD). Traditional lipid-lowering therapies, such as statins and PCSK9 inhibitors, have demonstrated significant efficacy; however, a subset of patients remains refractory or intolerant to these options. Recent breakthroughs in RNA-based therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), offer novel approaches for precise modulation of lipid levels. This review explores the current landscape and clinical implications of RNA-based therapies for lipoprotein metabolism disorders, providing healthcare professionals with evidence-based insights for optimizing patient care.

Epidemiology / Disease Burden

Lipoprotein metabolism disorders are prevalent worldwide, with familial hypercholesterolemia (FH) affecting approximately 1 in 250 individuals and contributing significantly to premature coronary artery disease. Population-based studies have documented that dyslipidemia, including elevated LDL-C, triglycerides, and lipoprotein(a), is present in up to 40% of adults in Western countries. The burden is amplified by rising rates of obesity, diabetes, and sedentary lifestyles, leading to increased incidence of mixed dyslipidemias. The global impact of dyslipidemia-related ASCVD underscores the urgent need for effective, innovative therapies, particularly for patients with genetic or refractory lipid abnormalities.

Pathophysiology

Lipoprotein metabolism disorders arise from complex interactions between genetics, enzymatic activity, and environmental factors. Defective LDL receptor function, impaired apolipoprotein B catabolism, and increased PCSK9 activity are central to the pathogenesis of hypercholesterolemia. Elevated triglycerides often result from hepatic overproduction of VLDL or impaired lipolysis via lipoprotein lipase deficiency. Recent studies have highlighted the pathogenic role of lipoprotein(a) and its apolipoprotein(a) component in promoting atherothrombosis. RNA-based therapeutics target these molecular pathways by silencing genes such as APOB, PCSK9, and LPA, thereby reducing synthesis of atherogenic lipoproteins at the mRNA level.

Risk Factors

Genetic mutations (e.g., LDLR, APOB, PCSK9, LPA) are primary drivers of monogenic dyslipidemias, while polygenic risk and secondary factors such as metabolic syndrome, hypothyroidism, nephrotic syndrome, and lifestyle choices contribute to acquired forms. Family history, obesity, insulin resistance, and chronic alcohol use further modulate risk. Identification of high-risk individuals, including those with premature ASCVD or persistent dyslipidemia despite standard therapy, is critical for targeted intervention.

Clinical Features

Clinical presentation varies from asymptomatic laboratory findings to overt manifestations such as xanthomas, corneal arcus, and premature cardiovascular events. Homozygous familial hypercholesterolemia can present in childhood with tendon xanthomas and accelerated atherosclerosis. Severe hypertriglyceridemia may cause pancreatitis and eruptive xanthomas. Subclinical lipid abnormalities necessitate vigilant screening and risk stratification, particularly in patients with strong family histories or unexplained early-onset ASCVD.

Diagnosis

Diagnosis is established through fasting lipid profiles, with measurement of total cholesterol, LDL-C, HDL-C, triglycerides, and, increasingly, lipoprotein(a). Genetic testing is indicated in suspected monogenic disorders or when family screening is required. Advanced lipid profiling (e.g., apolipoprotein quantification, LDL particle size) and imaging modalities (e.g., coronary calcium scoring) may aid in risk assessment and therapeutic decision-making. Accurate phenotyping is essential for tailoring therapy, especially when considering RNA-based interventions.

Treatment & Management

First-line management includes lifestyle modification and statins, often in combination with ezetimibe or PCSK9 inhibitors for high-risk patients. Fibrates, niacin, and bile acid sequestrants are used for specific lipid abnormalities, but their use is limited by side effects and modest efficacy. Despite maximal therapy, a significant proportion of patients fail to achieve lipid targets or experience adverse effects, highlighting the need for alternative strategies. Therapeutic apheresis is reserved for selected severe cases, such as homozygous FH or refractory hypertriglyceridemia, but is resource-intensive and not widely accessible.

Recent Advances / Emerging Therapies

RNA-based therapeutics have revolutionized the treatment landscape by enabling targeted gene silencing. Antisense oligonucleotides (e.g., mipomersen for APOB, volanesorsen for APOC3) and siRNAs (e.g., inclisiran targeting PCSK9, olpasiran targeting LPA) have demonstrated robust lipid-lowering effects in clinical trials. Inclisiran, administered biannually, offers sustained LDL-C reduction with a favorable safety profile, addressing adherence challenges. Volanesorsen and other ASOs have shown efficacy in severe hypertriglyceridemia by modulating apolipoprotein C-III synthesis. Ongoing trials are evaluating the long-term cardiovascular benefits and potential off-target effects of these agents. Emerging RNA-based therapies hold promise for patients with genetic dyslipidemias, statin intolerance, or high Lp(a) levels unresponsive to conventional therapy.

Guideline Recommendations

Major guidelines (AHA/ACC, ESC/EAS) currently recommend statins as the cornerstone of lipid management, with PCSK9 inhibitors and ezetimibe as adjuncts for high-risk or refractory cases. RNA-based therapies are not yet universally incorporated into frontline guidelines but are recognized as valuable adjuncts for select populations, such as homozygous FH and patients with persistently elevated Lp(a). Clinicians should assess individual cardiovascular risk, therapeutic response, and tolerability when considering RNA-based agents, in alignment with evolving evidence and regulatory approvals.

Conclusion

RNA-based therapeutics represent a paradigm shift in the management of lipoprotein metabolism disorders, offering precise, mechanism-driven interventions for patients inadequately served by traditional therapies. Ongoing clinical trials and long-term outcome data will further define their role in routine clinical practice. For healthcare professionals, familiarity with the indications, mechanisms, and safety profiles of RNA-based agents is essential for optimizing cardiovascular risk reduction in high-risk patients. As the field evolves, integration of RNA-based therapies into comprehensive lipid management protocols promises to improve patient outcomes and reduce the global burden of ASCVD.